MR imaging of soft‐tissue masses: Role of gadopentetate dimeglumine

Richard A. Benedikt, James S. Jelinek, Mark J. Kransdorf, Richard P. Moser, B. Hudson Berrey

Research output: Contribution to journalArticlepeer-review

31 Scopus citations


To assess the effectiveness of gadopentetate dimeglumine in the magnetic resonance (MR) imaging evaluation of soft‐tissue masses without osseous involvement, 30 patients underwent MR imaging before and after administration of contrast material (0.1 mmol/ kg) of the 30 lesions, 22 were benign and eight were malignant; histologic confirmation was available in all lesions except one benign lesion. Overall, enhancement was detected in 26 (87%) of 30 lesions: 18 (82%) of the 22 benign lesions and eight (100%) of eight malignant lesions. Enhancement was characterized as homogeneous (two [11%] benign lesions, two [25%] malignant lesions), inhomogeneous (11 [61%] benign lesions, six [75%] malignant lesions), or peripheral (five [28%] benign lesions, no malignant lesions) of the 19 lesions assessed for a change in enhancement over time, seven (37%) showed an increase and two (11%) showed a decrease in signal intensity. The authors conclude that benign and malignant soft‐tissue lesions could not be differentiated solely on the basis of enhancement (pattern, degree, or time course).

Original languageEnglish (US)
Pages (from-to)485-490
Number of pages6
JournalJournal of Magnetic Resonance Imaging
Issue number3
StatePublished - 1994


  • Angloma 40.362
  • Contrast enhancement
  • Gadolinium
  • Histiocytoma 40.3285
  • Soft tissues, MR. 40.12143
  • Soft tissues, infection, 40.24
  • Soft tissues, neoplasms. 40.36, 40.37

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'MR imaging of soft‐tissue masses: Role of gadopentetate dimeglumine'. Together they form a unique fingerprint.

Cite this